Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells.

Benteyn D, Heirman C, Thielemans K, Bonehill A.

Methods Mol Biol. 2016;1428:115-23. doi: 10.1007/978-1-4939-3625-0_7.

PMID:
27236795
2.

Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.

Iwabuchi M, Narita M, Uchiyama T, Iwaya S, Oiwa E, Nishizawa Y, Hashimoto S, Bonehill A, Kasahara N, Takizawa J, Takahashi M.

Mol Med Rep. 2015 Aug;12(2):2443-50. doi: 10.3892/mmr.2015.3685. Epub 2015 Apr 24.

3.

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.

Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B.

Cancer Immunol Immunother. 2015 Mar;64(3):381-8. doi: 10.1007/s00262-014-1642-8. Epub 2014 Dec 30.

PMID:
25548092
4.

mRNA-based dendritic cell vaccines.

Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K.

Expert Rev Vaccines. 2015 Feb;14(2):161-76. doi: 10.1586/14760584.2014.957684. Epub 2014 Sep 8. Review.

PMID:
25196947
5.

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.

Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K.

Cancer Immunol Immunother. 2014 Sep;63(9):959-67. doi: 10.1007/s00262-014-1558-3. Epub 2014 May 31. Review.

PMID:
24878889
6.

Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules.

Benteyn D, Van Nuffel AM, Wilgenhof S, Bonehill A.

Methods Mol Biol. 2014;1139:3-15. doi: 10.1007/978-1-4939-0345-0_1.

PMID:
24619665
7.

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.

Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A.

Mol Ther Nucleic Acids. 2013 Nov 19;2:e134. doi: 10.1038/mtna.2013.54.

8.

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.

Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Ann Oncol. 2013 Oct;24(10):2686-93. doi: 10.1093/annonc/mdt245. Epub 2013 Jul 31.

9.

Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.

Pen JJ, De Keersmaecker B, Maenhout SK, Van Nuffel AM, Heirman C, Corthals J, Escors D, Bonehill A, Thielemans K, Breckpot K, Aerts JL.

J Immunol. 2013 Aug 15;191(4):1976-83. doi: 10.4049/jimmunol.1201008. Epub 2013 Jul 10.

10.

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL).

Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

Biomed Res Int. 2013;2013:976383. doi: 10.1155/2013/976383. Epub 2013 Jan 3.

11.

Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy.

Van Nuffel AM, Wilgenhof S, Thielemans K, Bonehill A.

Oncoimmunology. 2012 Nov 1;1(8):1392-1394.

12.

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.

Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N.

Eur J Immunol. 2012 Jun;42(6):1417-28. doi: 10.1002/eji.201141954.

13.

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, van der Bruggen P, Coulie PG, Neyns B, Thielemans K, Bonehill A.

Mol Ther. 2012 May;20(5):1063-74. doi: 10.1038/mt.2012.11. Epub 2012 Feb 28.

14.

Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.

Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, Thielemans K.

Cancer Res. 2012 Apr 1;72(7):1661-71. doi: 10.1158/0008-5472.CAN-11-2957. Epub 2012 Feb 15.

15.

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

J Immunol Methods. 2012 Mar 30;377(1-2):23-36. doi: 10.1016/j.jim.2011.12.010. Epub 2012 Jan 16.

PMID:
22269772
16.

Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.

Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2012 Jul;61(7):1033-43. doi: 10.1007/s00262-011-1176-2. Epub 2011 Dec 10.

PMID:
22159452
17.

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B.

J Immunother. 2011 Jun;34(5):448-56. doi: 10.1097/CJI.0b013e31821dcb31.

PMID:
21577140
18.

Engineering dendritic cells to enhance cancer immunotherapy.

Boudreau JE, Bonehill A, Thielemans K, Wan Y.

Mol Ther. 2011 May;19(5):841-53. doi: 10.1038/mt.2011.57. Epub 2011 Apr 5. Review.

19.

Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases.

Wilgenhof S, Pierret L, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Verfaillie G, Vandenbroucke F, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Melanoma Res. 2011 Apr;21(2):152-9. doi: 10.1097/CMR.0b013e328343ece0.

PMID:
21317818
20.

Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.

Van Nuffel AM, Corthals J, Neyns B, Heirman C, Thielemans K, Bonehill A.

Methods Mol Biol. 2010;629:405-52. doi: 10.1007/978-1-60761-657-3_27.

PMID:
20387165
21.

Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells.

De Keersmaecker B, Heirman C, Allard S, Bonehill A, Corthals J, Thielemans K, Aerts JL.

Hum Gene Ther. 2010 Apr;21(4):479-85. doi: 10.1089/hum.2009.080.

PMID:
19903083
22.

Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases.

Pierret L, Baren NV, Bonehill A, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Riet IV, Degreef E, Goossens A, Verfaillie G, Roseeuw D, Thielemans K, Neyns B.

Melanoma Res. 2009 Dec;19(6):385-90. doi: 10.1097/CMR.0b013e32832eabb5.

PMID:
19707165
23.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, Fran├žois V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

24.

Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.

Allard SD, Pletinckx K, Breckpot K, Heirman C, Bonehill A, Michiels A, van Baalen CA, Gruters RA, Osterhaus AD, Lacor P, Thielemans K, Aerts JL.

Vaccine. 2008 Jul 4;26(29-30):3735-41. doi: 10.1016/j.vaccine.2008.04.077. Epub 2008 May 20.

PMID:
18539368
25.

Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.

Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K.

Mol Ther. 2008 Jun;16(6):1170-80. doi: 10.1038/mt.2008.77. Epub 2008 Apr 22.

26.

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.

Michiels A, Tuyaerts S, Bonehill A, Heirman C, Corthals J, Thielemans K.

Methods Mol Biol. 2008;423:155-63. doi: 10.1007/978-1-59745-194-9_10.

PMID:
18370196
27.

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. Epub 2007 May 15. Review.

PMID:
17503040
28.

Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.

Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H, Breckpot K, Thielemans K, Aerts JL.

J Leukoc Biol. 2007 Jul;82(1):93-105. Epub 2007 Apr 20.

PMID:
17449724
29.

CD83 expression on dendritic cells and T cells: correlation with effective immune responses.

Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, Thielemans K, Breckpot K.

Eur J Immunol. 2007 Mar;37(3):686-95.

30.

Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.

Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C, Thielemans K, Aerts JL.

Gene Ther. 2006 Jul;13(13):1027-36. Epub 2006 Mar 2.

PMID:
16511519
31.

Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.

Dullaers M, Van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL, Thielemans K, Breckpot K.

Gene Ther. 2006 Apr;13(7):630-40.

PMID:
16355115
32.

Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response.

Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C, Heirman C, Thielemans K.

J Leukoc Biol. 2005 Oct;78(4):898-908. Epub 2005 Jul 21.

PMID:
16037410
33.

Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.

Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, van der Bruggen P, Thielemans K.

Gene Ther. 2005 May;12(9):772-82.

PMID:
15750615
34.

Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.

Bonehill A, Heirman C, Thielemans K.

J Gene Med. 2005 Jun;7(6):686-95. Review.

PMID:
15693037
35.

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.

Dullaers M, Breckpot K, Van Meirvenne S, Bonehill A, Tuyaerts S, Michiels A, Straetman L, Heirman C, De Greef C, Van Der Bruggen P, Thielemans K.

Mol Ther. 2004 Oct;10(4):768-79.

36.

Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells.

Breckpot K, Corthals J, Heirman C, Bonehill A, Michiels A, Tuyaerts S, De Greef C, Thielemans K.

Hum Gene Ther. 2004 Jun;15(6):562-73.

PMID:
15212715
37.

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K.

J Immunol. 2004 Jun 1;172(11):6649-57.

39.

Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells.

Tuyaerts S, Michiels A, Corthals J, Bonehill A, Heirman C, de Greef C, Noppe SM, Thielemans K.

Cancer Gene Ther. 2003 Sep;10(9):696-706.

PMID:
12944989
40.

Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.

Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, van der Bruggen P, Thielemans K.

J Gene Med. 2003 Aug;5(8):654-67.

PMID:
12898635

Supplemental Content

Loading ...
Support Center